Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer

Sarah L Hulin-Curtis, Dominique Petit, W Douglas Figg, Ann W Hsing, Juergen K V Reichardt

Research output: Contribution to journalArticle (Academic Journal)peer-review

7 Citations (Scopus)

Abstract

Incidences of prostate cancer in most countries are increasing owing to better detection methods; however, prevention with the use of finasteride, a very effective steroid 5α-reductase type II inhibitor, has been met with mixed success. A wide interindividual variation in response exists and is thought to be due to heritable factors. This article summarizes the literature that attempts to elucidate the molecular mechanisms of finasteride in terms of its metabolism, excretion and interaction with endogenous steroid molecules. We describe previously reported genetic variations of steroid-metabolizing genes and their potential association with finasteride efficacy. Based on the literature, we outline directions of research that may contribute to understanding the interindividual variation in finasteride prevention and to the future development of personalized medicine.
Original languageEnglish
Pages (from-to)1897-913
Number of pages17
JournalFuture Oncology
Volume6
Issue number12
DOIs
Publication statusPublished - Dec 2010

Keywords

  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
  • 5-alpha Reductase Inhibitors
  • Cytochrome P-450 CYP3A
  • Finasteride
  • Genetic Variation
  • Glucuronosyltransferase
  • Humans
  • Individualized Medicine
  • Male
  • Prostatic Neoplasms
  • Testosterone

Fingerprint Dive into the research topics of 'Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer'. Together they form a unique fingerprint.

Cite this